ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Asston Pharmaceuticals Ltd submitted its quarterly shareholding pattern disclosure, detailing the shareholding status of promoters and public shareholders for the period ended March 2026.
Asston Pharmaceuticals has submitted its 7th Annual Report for the financial year 2025-26. The report provides a comprehensive overview of the company's annual financial performance.
Asston Pharmaceuticals Limited announced its Annual General Meeting scheduled for September 29, 2026. The agenda includes adopting financial statements, appointing auditors, and revising remuneration for key managerial personnel.
Asston Pharmaceuticals allotted 24,10,431 equity shares at Rs. 115 per share via preferential allotment, raising Rs. 27.72 Crore. This increases the company's paid-up equity share capital.
Asston Pharmaceuticals announced the outcome of its board meeting, including auditor appointments, director re-appointment, and upcoming AGM scheduling. The board also proposed remuneration increases for directors.
Prakruti R Pali acquired 2,40,000 shares of Asston Pharmaceuticals Ltd through an open market purchase. Post-acquisition stake is 5.33%.
Asston Pharmaceuticals will hold a board meeting on September 4, 2026, to discuss auditor appointment, director remuneration increases, and the upcoming Annual General Meeting.
Asston Pharmaceuticals held an EGM on July 31, 2026. Shareholders approved a special resolution to issue equity shares on a preferential basis.
Asston Pharmaceuticals convened an EGM for July 31, 2026. Shareholders will vote on a special resolution to issue equity shares on a preferential basis.
Asston Pharmaceuticals convened an EGM for July 31, 2026. The agenda includes a Rs. 27.72 Crore preferential allotment of 24.10 lakh equity shares.